EPIX - ESSA Pharma Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.15
+0.16 (+3.21%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.99
Open5.50
Bid0.00 x 800
Ask0.00 x 1800
Day's Range5.00 - 5.57
52 Week Range1.41 - 5.75
Volume36,954
Avg. Volume42,938
Market Cap105M
Beta (3Y Monthly)2.19
PE Ratio (TTM)N/A
EPS (TTM)-1.75
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • How Many ESSA Pharma Inc. (CVE:EPI) Shares Did Insiders Buy, In The Last Year?
    Simply Wall St.

    How Many ESSA Pharma Inc. (CVE:EPI) Shares Did Insiders Buy, In The Last Year?

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...

  • Encode Ideas, L.P. Announces the Initiation of Research Coverage on ESSA Pharma, Inc.
    Newsfile

    Encode Ideas, L.P. Announces the Initiation of Research Coverage on ESSA Pharma, Inc.

    Dover, Delaware--(Newsfile Corp. - November 11, 2019) - Encode Ideas, L.P. Initiates Research on ESSA Pharma, Inc. (NASDAQ: EPIX). The full research publication is available here and available on our website at www.encodelp.com. A summary follows:Encode Ideas, L.P., a healthcare focused research firm, announced today it is initiating coverage on ESSA Pharma, Inc, (NASDAQ: EPIX) as a high conviction investment idea. ESSA is developing a new class of prostate cancer drugs, known as ...

  • CNW Group

    ESSA Pharma Grants Stock Options

    HOUSTON and VANCOUVER , Oct. 30, 2019 /CNW/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Corporation") announced that, pursuant to its stock option plan, it has granted incentive stock options to non – executive members of the Corporation's board of directors to purchase up to an aggregate of 225,000 common shares in the capital of the Corporation (the "Common shares"). The stock options will vest in 36 equal monthly instalments, with the first instalment vesting on the one-month anniversary of the grant date.

  • CNW Group

    ESSA Pharma Presents Data on EPI-7386 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    ESSA Pharma Presents Data on EPI-7386 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

  • CNW Group

    ESSA Announces Changes to its Board of Directors

    VANCOUVER and HOUSTON, TX , Oct. 18, 2019 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announces that Ari Brettman has been appointed to the board of the directors of the Company (the "Board") pursuant to a nomination right granted to Clarus Lifesciences III, L.P., now managed by Blackstone Life Sciences.

  • EPIX: New Preclinical Data for EPI-7386 Presented at ESMO 2019…
    Zacks Small Cap Research

    EPIX: New Preclinical Data for EPI-7386 Presented at ESMO 2019…

    By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update New Preclinical Data for EPI-7386 Presented at ESMO On September 28, 2019, ESSA Pharma Inc. (NASDAQ:EPIX) announced new preclinical data was presented at the European Society of Medical Oncology (ESMO) 2019 Congress. ESSA Pharma is developing a novel class of compounds, known as ‘anitens’, to treat prostate cancer

  • CNW Group

    ESSA Pharma Board of Directors Approves Stock Option Plan, RSU Plan and Option Grants

    VANCOUVER and HOUSTON , Oct. 7, 2019 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, hereby announces that, pursuant to the Company's existing stock option plan (the "Existing Option Plan"), it has granted incentive stock options ("Options") to certain directors, officers, employees and consultants of the Company to purchase up to an aggregate of 1,441,530 common shares in the capital of the Company (the "Common Shares"). The Options are exercisable on or before October 4, 2029 at the price of US$3.23 per Common share and are granted in accordance with the polices of the TSX Venture Exchange (the "TSXV") and the terms and conditions of the Existing Option Plan.

  • CNW Group

    ESSA Pharma Presents New Data on EPI-7386 at the European Society of Medical Oncology (ESMO) 2019 Congress

    HOUSTON and VANCOUVER , Sept. 28, 2019 /CNW/ - ESSA Pharma Inc. (EPIX) (EPI.V), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's lead Investigational New Drug ("IND") candidate at the 2019 American Urological Association ("AUA") Annual Meeting. In an oral poster presentation titled, "EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer", a deeper preclinical characterization of EPI-7386 was presented.

  • CNW Group

    ESSA to Present at Ladenburg Thalmann Healthcare Conference

    Nasdaq: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Ladenburg Thalmann Helathcare Conference on Tuesday September 24, 2019 at 9:30am EDT at the Sofitel New York City in New York . R. Parkinson, Chief Executive Officer, will provide a corporate overview of the Company's business and will be available for one-on-one meetings from on September 24 , 2019.  ESSA's Chief Financial Officer, David S. Wood , and Chief Operating Officer, Peter Virsik , will also be in attendance.

  • CNW Group

    ESSA Pharma Completes Public Offering and Concurrent Private Placement for Aggregate Gross Proceeds of US$36 Million

    TSXV: EPI) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that, further to its previously announced equity offering, it has closed a public offering of equity securities of the Company in Canada and a concurrent private placement of equity securities in the United States for aggregate gross proceeds of US$36 million (the "Offering"). The Offering was led by Soleus Capital and included RA Capital Management as a new investor.

  • Zacks Small Cap Research

    EPIX: Initiating Coverage of ESSA Pharma Inc.; Unique Mechanism Targeting the Androgen Receptor in Prostate Cancer…

    We are initiating coverage of ESSA Pharma Inc. (EPIX) with a $6.00 valuation. ESSA is a biopharmaceutical company developing treatments for prostate cancer that are no longer responding to current therapies. The company is developing a series of compounds (‘anitens’) that disrupt the androgen receptor (AR) signaling pathway through a unique mechanism of action that targets the N-terminal domain (NTD) of the AR, as opposed to the ligand-binding domain (LBD) of the AR that is targeted by all other AR-directed prostate cancer treatments.

  • Benzinga

    10 Biopharmaceutical Companies Trying To Cure Cancer

    Cancer. Research shows nearly every sixth death in the world is due to the disease, making it the second leading cause of death behind cardiovascular diseases. The global pharmaceutical industry is estimated ...

  • PR Newswire

    ESSA Pharma Announces $36 Million Public Offering of Common Stock and Concurrent Private Placement

    TSXV: EPI) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce a public offering of equity securities of the Company in Canada and a concurrent private placement of equity securities in the United States (the "Offering"). The Offering is being led by Soleus Capital and includes RA Capital Management as a new investor.

  • CNW Group

    ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2019

    ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2019